vs
Side-by-side financial comparison of Cellectis S.A. (CLLS) and Presurance Holdings, Inc. (PRHI). Click either name above to swap in a different company.
Cellectis S.A. is the larger business by last-quarter revenue ($9.5M vs $5.7M, roughly 1.7× Presurance Holdings, Inc.). Cellectis S.A. runs the higher net margin — -265.9% vs -369.2%, a 103.3% gap on every dollar of revenue. On growth, Cellectis S.A. posted the faster year-over-year revenue change (375.0% vs -61.4%).
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina.
CLLS vs PRHI — Head-to-Head
Income Statement — Q2 FY2024 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $5.7M |
| Net Profit | $-25.3M | $-17.0M |
| Gross Margin | — | — |
| Operating Margin | -181.1% | -322.7% |
| Net Margin | -265.9% | -369.2% |
| Revenue YoY | 375.0% | -61.4% |
| Net Profit YoY | -51.9% | 32.9% |
| EPS (diluted) | $-0.28 | $-1.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $5.7M | ||
| Q3 25 | — | $6.8M | ||
| Q2 25 | — | $16.1M | ||
| Q1 25 | — | $15.9M | ||
| Q4 24 | — | $14.7M | ||
| Q3 24 | — | $16.0M | ||
| Q2 24 | $9.5M | $17.9M | ||
| Q1 24 | — | $18.6M |
| Q4 25 | — | $-17.0M | ||
| Q3 25 | — | $-4.0M | ||
| Q2 25 | — | $2.1M | ||
| Q1 25 | — | $522.0K | ||
| Q4 24 | — | $-25.4M | ||
| Q3 24 | — | $52.8M | ||
| Q2 24 | $-25.3M | $-4.0M | ||
| Q1 24 | — | $74.0K |
| Q4 25 | — | -322.7% | ||
| Q3 25 | — | -42.7% | ||
| Q2 25 | — | -22.6% | ||
| Q1 25 | — | -27.9% | ||
| Q4 24 | — | -177.1% | ||
| Q3 24 | — | -45.8% | ||
| Q2 24 | -181.1% | -24.3% | ||
| Q1 24 | — | 2.7% |
| Q4 25 | — | -369.2% | ||
| Q3 25 | — | -58.2% | ||
| Q2 25 | — | 12.7% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | -172.4% | ||
| Q3 24 | — | 329.6% | ||
| Q2 24 | -265.9% | -22.1% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | $-1.40 | ||
| Q3 25 | — | $-0.32 | ||
| Q2 25 | — | $0.17 | ||
| Q1 25 | — | $0.04 | ||
| Q4 24 | — | $-2.08 | ||
| Q3 24 | — | $4.32 | ||
| Q2 24 | $-0.28 | $-0.32 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $149.0M | $52.1M |
| Total DebtLower is stronger | — | $12.2M |
| Stockholders' EquityBook value | $148.6M | $9.0M |
| Total Assets | $407.1M | $239.3M |
| Debt / EquityLower = less leverage | — | 1.36× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $52.1M | ||
| Q3 25 | — | $62.3M | ||
| Q2 25 | — | $58.3M | ||
| Q1 25 | — | $52.3M | ||
| Q4 24 | — | $48.8M | ||
| Q3 24 | — | $53.6M | ||
| Q2 24 | $149.0M | $33.0M | ||
| Q1 24 | — | $41.0M |
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $12.1M | ||
| Q2 25 | — | $12.1M | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | — | $16.5M | ||
| Q2 24 | — | $24.8M | ||
| Q1 24 | — | $24.9M |
| Q4 25 | — | $9.0M | ||
| Q3 25 | — | $25.3M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | — | $25.6M | ||
| Q4 24 | — | $21.5M | ||
| Q3 24 | — | $49.1M | ||
| Q2 24 | $148.6M | $-1.2M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | — | $239.3M | ||
| Q3 25 | — | $285.0M | ||
| Q2 25 | — | $283.3M | ||
| Q1 25 | — | $277.1M | ||
| Q4 24 | — | $281.7M | ||
| Q3 24 | — | $299.9M | ||
| Q2 24 | $407.1M | $292.9M | ||
| Q1 24 | — | $301.1M |
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 9.75× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.9M | $-43.9M |
| Free Cash FlowOCF − Capex | $27.6M | — |
| FCF MarginFCF / Revenue | 290.5% | — |
| Capex IntensityCapex / Revenue | 13.2% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-43.9M | ||
| Q3 25 | — | $-681.0K | ||
| Q2 25 | — | $-2.8M | ||
| Q1 25 | — | $-15.3M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-10.7M | ||
| Q2 24 | $28.9M | $-10.1M | ||
| Q1 24 | — | $8.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $27.6M | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 290.5% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 13.2% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1.34× | ||
| Q1 25 | — | -29.23× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -0.20× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 110.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
